Amarin Corporation plc, each representing one Ordinary Share (AMRN): Price and Financial Metrics

Amarin Corporation plc, each representing one Ordinary Share (AMRN)

Today's Latest Price: $4.60 USD

0.12 (2.68%)

Updated Nov 25 7:55pm

Add AMRN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AMRN Stock Summary

  • The price/operating cash flow metric for Amarin Corp Plc is higher than 98.32% of stocks in our set with a positive cash flow.
  • For AMRN, its debt to operating expenses ratio is greater than that reported by just 7.35% of US equities we're observing.
  • With a year-over-year growth in debt of -73.05%, Amarin Corp Plc's debt growth rate surpasses merely 3.56% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Amarin Corp Plc, a group of peers worth examining would be EVER, HAYN, TREE, VG, and BOOM.
  • Visit AMRN's SEC page to see the company's official filings. To visit the company's web site, go to

AMRN Stock Price Chart Interactive Chart >

Price chart for AMRN

AMRN Price/Volume Stats

Current price $4.60 52-week high $26.12
Prev. close $4.48 52-week low $3.36
Day low $4.46 Volume 6,525,100
Day high $4.68 Avg. volume 9,827,133
50-day MA $4.58 Dividend yield N/A
200-day MA $7.35 Market Cap 1.80B

Amarin Corporation plc, each representing one Ordinary Share (AMRN) Company Bio

Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States. The company was founded in 1989 and is based in Dublin, Ireland.

AMRN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$4.60$0 -100%

We started the process of determining a valid price forecast for Amarin Corp Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Amarin Corp Plc ranked in the 0th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Amarin Corp Plc ended up being:

  • Its compound free cash flow growth rate, as measured over the past 0.52 years, is -0.94% -- higher than only 0.19% of stocks in our DCF forecasting set.
  • Relative to other stocks in its sector (Healthcare), Amarin Corp Plc has a reliance on debt greater than merely 10.01% of them.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMRN, try AGHC, ALC, ATRS, MOR, and PACB.

AMRN Latest News Stream

Event/Time News Detail
Loading, please wait...

AMRN Latest Social Stream

Loading social stream, please wait...

View Full AMRN Social Stream

Latest AMRN News From Around the Web

Below are the latest news stories about Amarin Corp Plc that investors may wish to consider to help them evaluate AMRN as an investment opportunity.

Amarin (AMRN) Investor Presentation - Slideshow

The following slide deck was published by Amarin Corporation plc in conjunction with this event....

SA Transcripts on Seeking Alpha | September 16, 2020

Amarin (AMRN): Vascepa’s International Opportunity Remains Intact, Says Analyst

The markets might be in turmoil, but spare a thought for the current woes at biotech Amarin (AMRN). Over the past 7 trading sessions, shares have retreated by 44% as investors charged to the exit doors following a botched date in court.Last week, an appeals court rejected Amarin’s appeal concerning a

Yahoo Finance | September 11, 2020

Amarin: 'The Future Ain't What It Used To Be'

Background If unaware, the title is a quote from Yogi Berra, that great baseball player and common-man philosopher. So, when the U.S. Court of Appeals affirmed the decision of the U.S. District Court for the district of Nevada and ruled Amarin’s (AMRN) patents for Vascepa obvious and, thus, invalid, it...

StrategyDoc on Seeking Alpha | September 9, 2020

The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations

After remaining steady in the first three sessions of the week ended Sept. 4, biotech stocks pulled back along with the broader market in a tech-induced sell-off. Barring anything COVID-19-related , the news flow was fairly light ahead of the Labor Day holiday. Amarin Corporation plc (NASDAQ: AMRN ) took a severe beating after losing a patent appeal related to its synthetic fish oil pill Vascepa. The stock lost over 40% during the week, attributable primarily to the adverse ruling and to a smaller extent to the market sell-off. Here are the key catalysts for the unfolding week. Conferences Citi's 15th Annual BioPharma Conference: Sept. 8-11 Wells Fargo 2020 Virtual Healthcare Conference: Sept. 9-10 Baird 2020 Global Healthcare Conference: Sept. 9-10 BTIG Virtual Biotechnology Conference...

Benzinga | September 6, 2020

Fed Circuit swiftly rejects Amarin bid to save heart drug patents on appeal

A federal appeals court on Thursday dealt a major setback to pharmaceutical company Amarin Corp, affirming a patent ruling that opened the door to generic versions of its heart drug Vascepa.

Reuters | September 3, 2020

Read More 'AMRN' Stories Here

AMRN Price Returns

1-mo -4.76%
3-mo -37.50%
6-mo -32.94%
1-year -77.56%
3-year 44.65%
5-year 118.01%
YTD -78.54%
2019 57.53%
2018 239.40%
2017 30.19%
2016 62.96%
2015 92.86%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.9192 seconds.